EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Factors Associated with the Detection of Actionable Genomic Alterations Using Liquid Biopsy in Biliary Tract Cancer

Hiroshi Shimizu iD, Rei Suzuki iD, Hiroyuki Asama, Kentaro Sato, Kento Osawa, Rei Ohira iD, Keisuke Kudo, Mitsuru Sugimoto, Hiromasa Ohira

Cancers · 19.09.2025 · 17 (18) · 3071

DOI: 10.3390/cancers17183071 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancers, online erschienen am 19.09.2025. Verfasst von Hiroshi Shimizu und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, Fukushima Medical University School of Medicine, Fukushima 960-1295, Japan. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Blood-based comprehensive genomic profiling (CGP), a form of liquid biopsy, is often used for biliary tract cancer (BTC) when tissue-based CGP (tissue CGP) is unavailable, despite lower detection rates. This study explored factors linked to detecting actionable genomic alterations to optimize its use.

Methods

We retrospectively analyzed BTC cases in Japan’s C-CAT (June 2019–January 2025), restricting panel comparisons to FoundationOne® CDx (F1; n = 5019) and FoundationOne® Liquid CDx (F1L; n = 1550). Missing covariates were handled by multiple imputations (m = 20). Between-panel balance used 1:1 propensity-score matching (caliper 0.2). Outcomes were modeled with logistic regression. Targets included MSI-H, TMB-H, FGFR2/RET/NTRK fusions, BRAF V600E, KRAS G12C, IDH1 mutations, and ERBB2 amplification. An exploratory analysis stratified results by the number of prespecified enrichment factors (0–4). Liquid biopsy was performed using plasma-based comprehensive genomic profiling assays (FoundationOne® Liquid).

Results

Missingness was low; after matching (n = 1549 per group) covariates were well balanced (all|SMD|≤0.05). Detection of any actionable alteration was lower with F1L than F1 (16.8% vs. 24.8%; OR 0.61, 95% CI 0.49–0.75; p < 0.001). F1L also had lower TMB-H (OR 0.62, 0.43–0.90; p = 0.01) and ERBB2 amplification (OR 0.42, 0.31–0.57; p < 0.001), with no significant differences for MSI-H, IDH1, KRAS G12C, or BRAF V600E. Within F1L, non-perihilar location (OR 2.05), liver (1.90), lymph-node (1.41), and lung metastases (1.52) predicted detection of actionable genomic alterations. F1L detection increased from 5.8% (zero factors) to 32.8% (four factors), approximating tissue at three factors.

Conclusions

The utility of liquid biopsy can be maximized by carefully selecting samples on the basis of conditions that increase the detection rate.

Schlagwörter

Stichwörter der Autor:innen

biliary tract cancercholangiocarcinomagenomic profileliquid biopsy

Autor:innen und Institutionen

  • Department of Gastroenterology, Fukushima Medical University School of Medicine, Fukushima 960-1295, Japan.

ORCID-Profile: Hiroshi Shimizu, Rei Suzuki, Rei Ohira

Zitieren

APA

Shimizu, H., Suzuki, R., Asama, H., Sato, K., Osawa, K., Ohira, R., Kudo, K., Sugimoto, M., & Ohira, H. (2025). Factors Associated with the Detection of Actionable Genomic Alterations Using Liquid Biopsy in Biliary Tract Cancer. Cancers, 17(18), 3071. https://doi.org/10.3390/cancers17183071

Vancouver

Shimizu H, Suzuki R, Asama H, Sato K, Osawa K, Ohira R, et al. Factors Associated with the Detection of Actionable Genomic Alterations Using Liquid Biopsy in Biliary Tract Cancer. Cancers. 2025;17(18):3071. doi:10.3390/cancers17183071

BibTeX
@article{Shimizu2025,
  author = {Shimizu, Hiroshi and Suzuki, Rei and Asama, Hiroyuki and Sato, Kentaro and Osawa, Kento and Ohira, Rei and Kudo, Keisuke and Sugimoto, Mitsuru and Ohira, Hiromasa},
  title = {Factors Associated with the Detection of Actionable Genomic Alterations Using Liquid Biopsy in Biliary Tract Cancer},
  journal = {Cancers},
  year = {2025},
  volume = {17},
  number = {18},
  pages = {3071},
  doi = {10.3390/cancers17183071}
}
Kostenlos starten →